BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-153@catalystbrief.girapphe.com
DTSTAMP:20261118T181557Z
LAST-MODIFIED:20261118T181557Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: AstraZeneca — Anifrolumab (blinded) [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Determine Effectiveness of Anifrolu
 mab In SYstemic Sclerosis (DAISY).\nSource: https://clinicaltrials.gov/stu
 dy/NCT05925803\nhttps://catalystbrief.girapphe.com/e/153?lang=en\nNot inve
 stment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/153?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
